Thymos Health
Your Ulcerative Colitis Journey

Still flaring.
Still cycling through medications.
Still no real answers.

You're not alone. This is how ulcerative colitis (UC) is typically managed — and an honest look at what that journey costs over time.

499K Americans are living with ulcerative colitis.1
46% are first told it's IBS or stress.2
5+ doctors are typically seen before a correct diagnosis.3
24 sick days are lost per year, on average.4

How ulcerative colitis is typically treated

Most insurance plans follow a step-therapy protocol — starting with established treatments before moving to newer options.

Mark where you are in your journey and we'll show you the full picture.

Step 1: Your doctor starts you on Azathioprine
Imuran / Mercaptopurine — daily oral tablet
What your doctor says
"This suppresses the immune response causing your inflammation. Give it 3–6 months."
44% don't respond5
26% can't tolerate it6
Annual drug cost (generic) ~$0
Providers seen before this was prescribed
Providers involved while on this drug
How long were you on Azathioprine?
What happened?
Monitoring cost (labs every 3 months, year 1)
~$600–$1,200
44% of patients move to Step 2
Step 2: You graduate to Adalimumab
Hulio / Humira biosimilar — injection every 2 weeks
What your doctor says
"This is a biologic — it targets a specific protein causing your inflammation. Most patients see meaningful results."
22.8 clinic visits in the year before reaching this step15
30% never respond at all7
58% lose response over time8,9
Annual cost before insurance (AWP) ~$103,000
Providers seen before escalating to this biologic
Providers involved while on this biologic
How long were you on Adalimumab?
What happened?
Your coinsurance for this drug
Your estimated annual out-of-pocket for this drug
$20,600
58% eventually lose response — move to Step 3
Step 3: You move to Etrasimod
Velsipity — daily oral tablet (S1P receptor modulator)
What your doctor says
"This is a newer drug that works differently from biologics. Let's see how you respond."
Standard biologics haven't provided relief
15% annual surgery risk at this stage10
Annual cost — confirm with your plan ~$96,000
Providers seen before reaching this step
Providers involved while on this drug
How long have you been on Etrasimod?
What happened?
For some patients, surgical options become relevant
When medications haven't been enough Surgical options
Colectomy — partial or full removal of the colon
What Your Doctor says
"For patients who haven't responded to available medications, surgery can offer lasting relief from symptoms."
2.5× higher colorectal cancer risk11
$55K–$83K
First-year total cost (commercial insurance)
4–11 days
Hospital stay (lap. vs. open surgery)
2–3 mo
Until full energy & recovery
81%
Experience ongoing quality-of-life challenges
Recovery timeline
Hospital — laparoscopic surgery 4–5 days
Hospital — open surgery 8–11 days
Light activity 1–2 weeks
Return to desk work 2–4 weeks
Physical / manual labor 4–6 weeks
No lifting over 10 lbs 6 weeks
30-day readmission rate 7–23%
What changes long-term
🚽 Bowel habits change permanently. Loose stools, urgency, and increased frequency are common for months. 46% still take GI medication years later.
🩺 Ostomy risk: 40–44% of colectomy patients end up with a permanent ostomy — significantly affecting body image, sexual function, and daily life.
🧠 Mental health impact. Depression affects 39–43% of ostomy patients — rising from 6% pre-op to 31% by one year.12,13 Women have 2× the odds of clinical depression vs. men (aOR 2.08). Men score significantly worse on overall psychosocial adjustment and social engagement post-ostomy (p<0.001).14 Patients aged 19–45 carry 52% higher anxiety risk than those over 65. Both sexes are underscreened.
💊 Lifelong supplementation. Vitamin B12, D, A, E, K, iron, calcium, and magnesium deficiencies often require ongoing management.
📊 First-year mortality risk is 15–30% above baseline — far higher than the commonly cited 30-day figure of 1–3%.

What ulcerative colitis is really costing you

Your copay isn't the whole story. Ulcerative colitis costs you income, productivity, and career opportunities the system never puts on the receipt.

Based on your journey above–adjust the numbers to match your situation.
Sick days missed in the last 12 months
Your hourly wage (for lost income calculation)
$
Your estimated total annual cost of ulcerative colitis $0
Drug out-of-pocket costs $0
Lost income (sick days) $0
Reduced productivity at work $0
98% of ulcerative colitis patients report at least one work impairment.4 Drug out-of-pocket costs based on your coinsurance selection for it above (or a typical default if you haven't reached it yet).
The Other Side of the Bill

What your insurer is paying

Ulcerative colitis imposes a substantial and rising cost on commercial insurers. Biologic drugs — not the colectomy patients often fear most — are the dominant cost driver, and step therapy requirements delay rather than reduce that spend.

Annual Payer Perspective — Commercial Insurance
What your health plan spends on your ulcerative colitis care each year
Based on your drug journey above · All figures reflect payer (insurer) paid portion, not patient out-of-pocket cost.
Estimated annual payer cost for your ulcerative colitis care $0
Biologic drug spend (payer portion ~80% of AWP)
Adalimumab AWP ~$103,000/yr; etrasimod ~$96,000/yr — biologics and targeted oral therapies are the dominant driver of total ulcerative colitis spend
$0
Non-drug medical costs (GI visits, labs, imaging, ED)
Patients accumulate a mean of 22.8 outpatient encounters/yr before biologic initiation; 37% have at least one ED visit15
~$7,200
Biologic-treated ulcerative colitis patients cost payers substantially more than those on conventional therapy alone — commercial claims analyses report total annual healthcare costs 3–6× higher once a patient escalates to biologic therapy.16 Annual colectomy rates run 9–15% depending on prior biologic exposure, adding a $55,000–$83,000 one-time cost spike on top of ongoing drug spend.10
⚑ Why early biologic access saves payers money
Step therapy requirements mandate a thiopurine trial — and often a first anti-TNF failure — before newer mechanisms are approved, adding months of active, undertreated inflammation. That inflammation drives the loss of response that forces dose escalation and drug switching, and it accrues the colonic damage behind the 9–15% annual colectomy rate10 — costs that land on the payer regardless of which drug tier delayed adequate control.
Understanding Your Risk

What the research shows over time

Clinical data on ulcerative colitis outcomes can help you have more informed conversations with your care team about long-term management.

Based on peer-reviewed clinical data
Long-term outcomes for ulcerative colitis patients on step therapy
💊
58% of adalimumab patients eventually lose response — often within the first 1–2 years of treatment8,9
🏥
15% annual colectomy rate among patients who haven't responded to biologic therapy, based on a meta-analysis of 43 studies10
📈
2.5× higher colorectal cancer risk vs. the general population — rising with each year of uncontrolled inflammation11
💼
1 in 3 ulcerative colitis patients report job loss attributable to their condition4
✦ A different journey exists

Thymos Health offers another way

Conventional ulcerative colitis care focuses on managing symptoms through sequential medications. Thymos goes further – synthesizing diagnostics, medical history, symptoms, and lifestyle to understand what's driving your disease and customizes care based on your individual needs.

✓
Root cause treatment — not just another layer of suppression
✓
Whole system autoimmune specialist quarterbacks your labs, your team, your care plan
✓
24/7 personalized support — not just at your next appointment in 3 months
✓
80%+ symptom relief within 3 months across autoimmune conditions
No commitment. Takes 2 minutes.
Sources & Citations ▼
[1] Institute for Health Metrics and Evaluation (IHME). Global Burden of Disease Study 2023. United States prevalence: 148.93 per 100,000 (95% CI: 126.1–175.38).
URL: vizhub.healthdata.org/gbd-compare
[2] "S1033 Misdiagnosis of Inflammatory Bowel Disease." ACG Annual Scientific Meeting Abstract. American Journal of Gastroenterology, 2023.
URL: journals.lww.com — ACG 2023 abstract
[3] Health Union / CrohnsDisease.com Patient Survey, 2017. 62% of IBD patients visited their doctor 5 or more times before receiving a correct diagnosis.
URL: statista.com — IBD misdiagnosis survey
[4] Youssef N et al. "Work Productivity Impairment in Persons with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis." Journal of Crohn's & Colitis, 2024;18(9):1486–1498.
DOI: 10.1093/ecco-jcc/jjae025
[5] Timmer A et al. "Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis." Cochrane Database of Systematic Reviews, 2016.
DOI: 10.1002/14651858.CD000478.pub4
[6] Mallick R, Malik TF. "Use of Azathioprine in Ulcerative Colitis: A Comprehensive Review." Cureus, 2022;14(5):e24874.
DOI: 10.7759/cureus.24874
[7] Rutgeerts P et al. "Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis (ACT 1 and ACT 2)." New England Journal of Medicine, 2005;353:2462–2476. Primary non-response ~30–35%.
DOI: 10.1056/NEJMoa050516
[8] Savelkoul EHJ et al. "Systematic Review and Meta-analysis: Loss of Response and Need for Dose Escalation of Infliximab and Adalimumab in Ulcerative Colitis." Inflammatory Bowel Diseases, 2022. Adalimumab annual loss of response: 13.4% overall; 23.3% in year 1.
DOI: 10.1093/ibd/izac076
[9] Magro F et al. "Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response." Journal of Crohn's & Colitis, 2013. Cumulative loss of response: 58.3%.
PMID: 25389599
[10] "Selection strategy of second-line biologic therapies in adult patients with ulcerative colitis following prior biologic treatment failure: Systematic review and meta-analysis of 43 studies." Clinical Gastroenterology and Hepatology, 2024. Annual colectomy: 9% overall; 15% adalimumab-refractory.
PMID: 38403257  ·  DOI: 10.1016/j.cgh.2024.02.012
[11] Zhang L et al. "Colorectal cancer risk in ulcerative colitis: an updated population-based systematic review and meta-analysis." eClinicalMedicine (The Lancet), 2025. Standardised Incidence Ratio: 2.48 (95% CI: 1.64–3.76).
DOI: 10.1016/j.eclinm.2025.100201  ·  PMC: PMC12150054
[12] Kappelman MD et al. "Surgery, Stomas, and Anxiety and Depression in Inflammatory Bowel Disease." Colorectal Disease, 2020;22(5):557–567. n=10,481 IBD surgical patients. Women: depression aOR 2.08 [1.86–2.33], anxiety aOR 1.71 [1.50–1.94]. Age 19–45 vs. >65: anxiety aOR 1.52 [1.27–1.81].
DOI: 10.1111/codi.14905  ·  PMC: PMC7195997
[13] Targownik LE et al. "Similar risk of Depression and Anxiety following surgery or hospitalization for Crohn's disease and Ulcerative colitis." Am J Gastroenterol, 2013;108(4):594–601. Female depression aOR: 1.77 (CD), 2.92 (ulcerative colitis). 67% of depressed post-surgical CD patients had surgery before age 35.
DOI: 10.1038/ajg.2012.471  ·  PMC: PMC3627544
[14] Gautam S, Poudel A. "Effect of gender on psychosocial adjustment of colorectal cancer survivors with ostomy." Journal of Gastrointestinal Oncology, 2016;7(6):978–990. n=122. Men scored significantly lower on overall psychosocial adjustment (37.68 vs. 43.45, p=0.015) and social engagement (3.95 vs. 6.30, p<0.001) than women.
DOI: 10.21037/jgo.2016.09.02  ·  PMC: PMC5177570
[15] Wang Y et al. "Healthcare Resource Utilization and Costs Before and After Biologic Initiation in Patients with Ulcerative Colitis." BMC Gastroenterology, 2021;21:84. Mean 22.8 outpatient visits in the 12 months before biologic initiation; 37% had ≥1 ED visit.
DOI: 10.1186/s12876-021-01659-y  ·  PMC: PMC7967955
[16] Park KT et al. "The Cost of Inflammatory Bowel Disease: An Initiative from the Crohn's & Colitis Foundation." Inflammatory Bowel Diseases, 2020;26(1):1–10 (figures corroborated by Mehta F, Am Health Drug Benefits, 2016;9(6):318–318). Commercial claims analyses consistently report total annual healthcare costs 3–6× higher for biologic-treated ulcerative colitis patients compared with those managed on conventional therapy alone, driven overwhelmingly by drug acquisition cost rather than medical service use.
DOI: 10.1093/ibd/izz104